{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2012"],"condition":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"disease":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2140857"],"location":["Italy"],"study_start_month":["12"],"keyword":["VECTIBIX*INFUS 1FL 5ML 20MG/ML","Panitumumab","Cetuximab-refractory","VECTIBIX*INFUS 1FL 10ML 20MG/M"],"repository":["ECRIN MDR"],"study_status":["Active, not recruiting"],"additional_accession":[]},"is_claimable":false,"name":"A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer","description":"The purpose of this study is to assess if panitumumab is active enough to warrant comparative studies in patients with metastatic colorectal cancer that has progressed after treatment with cetuximab.","dates":{"creation":"2012-12-15"},"accession":"2140857","cross_references":{"ClinicalTrials___gov":["NCT01801904"],"EU Clinical Trials Register":["2010-024490-39"]}}